drugset / Trial / NCT03187210
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Phase 1/2
Suspended
20 enrolled
Insel Gruppe AG, University Hospital Bern
Mundipharma Medical Company · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The trial assess the maximum tolerated dose of a single-dose of Brentuximab Vedotin added to standard BeEAM chemotherapy (comprising Bendamustin, Etoposide, Cyclophosphamide and Melphalan) before autologous stem cell transplantation in CD30+ malignant lymphomas.
Timeline
- Start
- 2018-09-01
- Primary completion
- 2023-11-02
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | — |
| Background | Bendamustine | Small molecule | 200 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 400 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 200 mg/m2 | Intravenous |
| Background | Melphalan | Small molecule | 140 mg/m2 | Intravenous |